Corpseed

NPPA Extends Knee Implant Ceiling Prices Until 15 January 2027: Notification, Price List and Compliance Requirements

Department: Department of PharmaceuticalsAuthority: National Pharmaceutical Pricing AuthorityPublish: Applicable: 16-11-2026Product Quality ComplianceMedical Device and Pharmaceutical

Quick note

Below is the official summary and the reference document preview. Use β€œOpen PDF” for full screen view.

Schedule a Call Back

IN +91

Summary

The National Pharmaceutical Pricing Authority (NPPA) has extended the existing ceiling-price arrangement for orthopaedic knee implants used in knee replacement procedures until 15 January 2027. The extension was announced through Gazette Notification S.O. 6222(E), dated 13 November 2026, under the Ministry of Chemicals and Fertilizers.

The earlier arrangement was due to remain in force until 15 November 2026. With this latest order, the applicable price controls will continue for a further period of up to two months, unless NPPA issues another notification amending the position.

The NPPA knee implant price ceiling extension 2026 is relevant to manufacturers, importers, medical device distributors, hospitals and healthcare institutions handling these implants. The notification does not introduce a fresh price schedule. It continues the existing arrangement and expressly retains certain conditions from the original 2017 order.

NPPA Knee Implant Price Extension Notification at a Glance

The notification concerns the continuation of price controls on orthopaedic knee implants used in knee replacement systems.

Particulars Details
Issuing authority National Pharmaceutical Pricing Authority (NPPA)
Ministry Ministry of Chemicals and Fertilizers
Department Department of Pharmaceuticals
Notification number S.O. 6222(E)
Notification date 13 November 2026
Original notification S.O. 2668(E), dated 16 August 2017
Earlier extension S.O. 5190(E), dated 14 November 2025
Previous validity 15 November 2026
Extended validity 15 January 2027
Covered products Orthopaedic knee implants for knee replacement systems
Main development Extension of existing ceiling-price controls
Continuing provisions Notes (b) to (t) of S.O. 2668(E)
Regulatory status Extension in force, unless amended by a subsequent notification

The order gives affected businesses additional clarity about the period during which the existing ceiling-price framework continues to apply.

What Is the Regulatory Framework for Knee Implant Price Control in India?

The National Pharmaceutical Pricing Authority regulates prices under the Drugs (Prices Control) Order, 2013 (DPCO, 2013). It is responsible for implementing applicable drug price-control provisions and monitoring pricing under the powers assigned to it.

Orthopaedic knee implants were brought under price control through S.O. 2668(E), issued on 16 August 2017. NPPA exercised its powers under Paragraph 19 of DPCO, 2013, which permits price fixation in extraordinary circumstances when necessary in the public interest.

The original order was introduced in response to concerns about high implant prices and excessive trade margins. It established ceiling prices for different knee implant components and included conditions for manufacturers, importers, distributors and healthcare institutions. These provisions form the basis of the price-control arrangement that NPPA has now extended.

What Were the Previous NPPA Orders on Knee Implant Ceiling Prices?

The price controls introduced in August 2017 have been continued and revised through subsequent government notifications.

Original Knee Implant Price Notification in August 2017

NPPA issued S.O. 2668(E) on 16 August 2017 to fix ceiling prices for different components of primary and revision knee replacement systems.

The order classified implants according to the type of component and, in certain cases, the material used. It also prescribed conditions concerning selling prices, price lists, trade margins, billing and related compliance responsibilities.

Revision and Continuation of Ceiling Prices in September 2024

Through S.O. 3869(E), dated 10 September 2024, NPPA continued the applicable ceiling-price framework and published worked-out prices effective from 16 September 2024.

These figures covered 15 entries relating to primary and revision knee replacement systems. They are important because the November 2026 extension does not contain a replacement price schedule.

Previous Extension in November 2025

NPPA issued S.O. 5190(E) on 14 November 2025, extending the applicable price controls until 15 November 2026, or until further orders, whichever was earlier.

The notification also continued Notes (b) to (t) of the original 2017 order.

Latest Extension in November 2026

Under S.O. 6222(E), NPPA has extended the operation of the earlier arrangement until 15 January 2027, unless amended by another notification.

The relevant orders can be understood as follows:

Notification Date Main development
S.O. 2668(E) 16 August 2017 Original knee implant ceiling-price order
S.O. 3869(E) 10 September 2024 Continued the arrangement and published worked-out ceiling prices effective from 16 September 2024
S.O. 5190(E) 14 November 2025 Extended the applicable arrangement until 15 November 2026
S.O. 6222(E) 13 November 2026 Extended the arrangement until 15 January 2027, unless amended earlier

Several other extension orders were issued between 2017 and 2025. The table highlights the instruments most relevant to understanding the latest notification and the price schedule discussed below.

What Has Changed Under the NPPA November 2026 Notification?

The main change is the extension of the existing ceiling-price arrangement. Manufacturers and suppliers should not interpret the notification as permission to increase prices or introduce a different pricing structure.

Extension of the Existing Price Controls

The earlier order was applicable until 15 November 2026. NPPA has now extended its operation for a further period of up to two months, ending on 15 January 2027 unless amended sooner.

The extension provides continuity for businesses dealing in the affected implants. The applicable price-control framework therefore remains relevant during the extended period.

Continuation of Earlier Conditions

The November 2026 notification specifically states that Notes (b) to (t) of the 2017 order will remain in force during the currency of the latest order.

These provisions deal with matters such as pricing, trade margins, information supplied to hospitals, price-list display and certain responsibilities of manufacturers and institutions.

Businesses should review these conditions alongside the applicable price schedule rather than relying only on the two-page November notification.

Industry Representations Are Still Being Considered

NPPA has stated that representations received from manufacturers and industry associations are under consideration.

The order does not disclose a final decision on those representations or announce any resulting price revision.

Businesses should therefore rely on the applicable published orders until NPPA issues a subsequent notification changing the regulatory position.

Which Orthopaedic Knee Implants Are Covered Under NPPA Price Control?

The price-control framework covers specified components of primary knee replacement systems and revision knee replacement systems.

The distinction matters because NPPA specifies different ceiling prices for different components and material categories.

Primary Knee Replacement Systems

A primary knee replacement system is used in a patient's initial knee replacement procedure.

The price-control schedule includes components such as the femoral component, tibial component or tray, articulating surface or insert, patella, and specified combined tibial tray-and-insert components.

Certain entries distinguish between materials such as titanium alloy, oxidised zirconium alloy and cobalt-chromium alloy.

Revision Knee Replacement Systems

Revision knee replacement procedures involve replacing or correcting components of an earlier knee replacement.

The applicable schedule separately identifies femoral components, tibial components, inserts and patellar components used in revision systems.

The prices are specified component-wise rather than as one general amount for every revision procedure.

Special Orthopaedic Knee Implants

The original 2017 order also contains provisions concerning special orthopaedic knee implants used for cancer or tumour-related conditions.

These cases may involve specific pricing considerations under the original notification. The time-limited arrangements contained in the 2017 order should not be mistaken for new permissions beginning in November 2026.

Businesses handling these products should verify the applicable NPPA provisions for the particular implant.

What Are the NPPA Ceiling Prices for Knee Implants in India?

The September 2024 order, S.O. 3869(E), published worked-out ceiling prices effective from 16 September 2024. These figures were also reproduced in the NPPA price list published by the Kerala Drugs Control Department as updated on 27 August 2026.

The November 2026 notification extends the existing arrangement but does not issue a new numerical price list.

Ceiling Prices for Primary Knee Replacement Components

Component Material or specification Ceiling price (Rs.)
Femoral component Titanium alloy, coated 51,562.94
Femoral component Oxidised zirconium alloy 51,562.94
Femoral component Hi-flex 34,419.66
Femoral component Cobalt-chromium alloy and other applicable variants 32,063.79
Tibial component or tray Titanium alloy, coated 32,316.68
Tibial component or tray Oxidised zirconium alloy 32,316.68
Tibial component or tray Cobalt-chromium alloy and other applicable variants 22,613.69
Articulating surface or insert Any material 12,711.05
Patella Any material 5,443.79
Combined tibial tray and insert Polyethylene and other specified materials 17,249.76
Combined tibial tray and insert Metallic tibial component with specified insert materials 35,332.73

Ceiling Prices for Revision Knee Replacement Components

Component Material category Ceiling price (Rs.)
Femoral component Any material 83,546.87
Tibial component or tray Any material 41,553.82
Articulating surface or insert Any material 21,122.97
Patella Any material 5,443.79

Important: These are the worked-out component prices from the September 2024 schedule, not prices newly fixed on 13 November 2026. Each listed rate is for one unit of the specified component. Applicable GST must be considered in accordance with the relevant order.

Manufacturers and importers should verify the correct category, product specifications and applicable NPPA notification before deciding the permitted selling price.

Has NPPA Revised Knee Implant Ceiling Prices in November 2026?

No fresh numerical ceiling prices have been announced through S.O. 6222(E), dated 13 November 2026.

The notification extends the existing price-control arrangement. It does not contain a new component-wise price table, change the listed product categories or announce a revised pricing method.

The distinction is important for businesses reviewing their selling prices.

Regulatory matter Position under the November 2026 order
Existing price-control arrangement Extended
Period of applicability Extended until 15 January 2027
New numerical ceiling prices Not notified in this order
New implant categories Not introduced in this order
Notes (b) to (t) of the 2017 order Expressly continued
New registration requirement Not introduced by this order
Future price revision Not announced

Businesses should not assume that an extension of validity is the same as an upward or downward revision of the ceiling prices.

Any subsequent pricing change must be checked against the relevant official NPPA notification.

Which Conditions of the 2017 Knee Implant Price Order Remain Applicable?

The latest order continues Notes (b) to (t) of S.O. 2668(E). These conditions are important because compliance involves more than checking the numerical ceiling price.

1. Manufacturers Must Follow the Applicable Price Category

Note (b) requires manufacturers to comply with the ceiling prices applicable to the relevant implant category.

The original provision covers implants regardless of whether they are cementable or uncementable, gender-specific or unisex, subject to the qualifications stated in that note.

Businesses should identify the correct component and category before applying the relevant price.

2. Pricing and MRP Conditions Continue

Notes (d) to (g) deal with the pricing of implants, including the treatment of products sold above or below the applicable ceiling price, the calculation of maximum retail price (MRP), and the addition of eligible GST.

A manufacturer cannot simply treat the ceiling price as a reason to raise the MRP of a product that was already being sold at a lower price. The relevant conditions of the original order and DPCO, 2013, must be considered.

The ceiling-price framework also requires businesses to avoid adding charges that are not permitted under the applicable provisions.

3. Price Lists and Display Requirements Remain Relevant

The original order requires manufacturers to issue price lists under the relevant provisions of DPCO, 2013.

Note (i) refers to Form V and submission through the Integrated Pharmaceutical Database Management System (IPDMS), along with distribution of price information to the specified authorities and trade participants.

Note (j) requires distributors, dealers and institutions to display the price lists and supplementary price lists supplied by manufacturers or importers in a manner accessible to people wishing to consult them.

These are continuing provisions under the original framework, not new procedures introduced in November 2026.

4. Hospitals Must Provide Component-Wise Price Information

The 2017 order contains specific requirements for healthcare institutions billing patients for knee implants.

Note (n) requires hospitals, nursing homes and clinics to separately identify implant costs in estimates, proforma invoices and final bills.

The details include the relevant component cost, brand name, manufacturer or importer, batch number and specifications, along with other applicable information.

This helps patients understand the price of the implanted components instead of receiving only an unexplained overall implant charge.

5. Trade Margins Are Subject to Specified Limits

Notes (r) and (s) contain provisions concerning permissible trade margins.

The original order specifies different margins for certain product categories. These margins operate within the ceiling-price framework and must not be treated as additional charges that can automatically be added above the notified ceiling price.

Implant categories under the 2017 schedule Distributor/stockist margin Hospital/institution margin
Serial numbers 4, 7, 8, 9, 10 and 11 Up to 16% Up to 8%
Serial numbers 1, 2, 3, 5, 6 and 12–15 Up to 12% Up to 4%
Certain special implants priced under Note (c) Up to 16% Up to 8%

Where manufacturers sell directly to orthopaedic healthcare institutions without a distributor, Note (s) provides a separate maximum hospital margin of 16%.

The precise applicable margin must be assessed against the relevant component category and the original notification. The percentage limits should not be added together indiscriminately or treated as a new margin structure issued in 2026.

6. Supply and Overcharging Conditions Continue

The original order also includes provisions concerning the continued availability of implant brands and the avoidance of supply disruption.

Note (q) addresses the recovery of overcharged amounts along with interest under the applicable legal framework.

Note (t) identifies excess trade margins as a violation that may attract appropriate action under DPCO, 2013, and the Essential Commodities Act, 1955.

Businesses should read these requirements alongside the latest extension and any applicable subsequent directions.

How Does the NPPA Knee Implant Price Extension Affect Businesses?

The extension is relevant to several parts of the medical device supply chain. Its effect will depend on the products a business handles and its role in manufacturing, importing, supplying or billing for those implants.

Impact on Knee Implant Manufacturers

Manufacturers must continue to account for the applicable price-control provisions when deciding how covered implants are priced and supplied.

The extension also gives manufacturers a definite period for reviewing their pricing arrangements while NPPA considers the representations received from industry participants.

Manufacturers may need to pay particular attention to product classification, notified ceiling prices, existing MRPs, trade margins and the requirements concerning price information.

Impact on Medical Device Importers

Importers supplying covered knee implants in India should review the applicable pricing provisions before placing products in the market.

The original order uses a specific definition of manufacturer that includes certain importers and marketers for the purposes of that order.

Importers should also distinguish NPPA pricing obligations from separate medical device import licensing requirements administered under the applicable medical device regulatory framework.

The November 2026 extension does not itself introduce a new CDSCO import licence application.

Impact on Distributors and Medical Device Suppliers

Distributors and stockists handling covered knee implants need to take account of the relevant ceiling prices and trade-margin provisions.

Price-list display and the accuracy of information supplied through the distribution chain are also relevant.

Businesses operating through multiple suppliers or distribution arrangements should ensure that their commercial records and pricing decisions reflect the correct regulatory position.

Impact on Hospitals and Healthcare Institutions

Hospitals and other institutions using knee implants must consider the relevant pricing conditions when purchasing implants and billing patients.

The component-wise billing requirements under the original order are especially important for institutions providing knee replacement treatment.

Hospitals should maintain clear information about the implants used, including their specifications, manufacturers and applicable prices.

What Is the Difference Between Knee Implant Ceiling Prices and Total Knee Replacement Costs?

The NPPA ceiling price relates to the specified knee implant components. It should not be confused with the full cost of a knee replacement procedure.

A hospital's overall treatment bill may involve several separate services and expenses, including surgical care, professional fees, anaesthesia, hospital facilities and other treatment-related charges.

The November 2026 order does not fix a single all-inclusive price for knee replacement surgery.

At the same time, hospitals cannot use separate billing descriptions to disregard the provisions that apply to the regulated implant components. The original NPPA order contains requirements concerning component-wise pricing and related billing information.

What Should Knee Implant Manufacturers and Importers Do During the Extension Period?

The new notification does not introduce a separate application process. However, affected businesses should review their existing pricing and compliance arrangements.

The following checks can help businesses identify matters requiring attention:

  1. Check product applicability: Identify the implant components handled by the business and confirm whether they fall within the applicable NPPA schedule.
  2. Verify the notified ceiling price: Compare the relevant product specifications with the latest applicable component-wise price order rather than relying on an outdated internal list.
  3. Review MRP and selling-price records: Check whether existing pricing decisions reflect the relevant ceiling-price and MRP provisions.
  4. Examine trade margins: Review applicable distributor and institutional margin conditions, particularly where several entities participate in the supply chain.
  5. Check price-list compliance: Confirm that relevant statutory price-list requirements are being followed.
  6. Review supply and hospital billing information: Ensure the appropriate information is available to the responsible teams and institutions.
  7. Monitor further NPPA notifications: Track any subsequent order that may amend the current arrangement before 15 January 2027.

These checks are practical compliance recommendations based on the continuing framework. They should not be represented as a newly introduced statutory procedure under S.O. 6222(E).

Does the NPPA November 2026 Notification Require a New Registration or Licence?

The November 2026 order does not introduce a new registration, licence, certificate or application requirement for knee implant businesses.

Its subject is the extension of existing price controls.

Manufacturers and importers must still comply with any separate medical device licensing obligations applicable to their products and activities.

For instance, requirements concerning medical device manufacturing or import authorisation fall under the applicable medical device regulatory framework. Those requirements should not be confused with the ceiling-price extension.

Businesses seeking CDSCO medical device registration or a medical device import licence should assess those approvals separately, based on the relevant product classification and business activity.

What Are the Compliance Risks for Knee Implant Manufacturers and Suppliers?

The main compliance concern is the possibility of pricing or billing practices that do not meet the continuing requirements.

Businesses handling regulated knee implants should be particularly careful about the following areas:

  • Incorrect product classification: Applying a ceiling price meant for a different implant component or material category.
  • Excessive selling prices: Charging above the applicable ceiling price in circumstances prohibited by the relevant order.
  • Improper trade margins: Using margins that exceed the limits specified for the relevant category.
  • Incomplete price information: Failing to follow applicable requirements concerning price lists and disclosure of component-wise implant costs.
  • Outdated compliance records: Continuing to use superseded pricing information without reviewing later NPPA orders.
  • Supply-related non-compliance: Disregarding applicable conditions concerning the availability of regulated implant products.

Under Note (q) of the original 2017 order, non-compliance with the specified ceiling prices and conditions may result in recovery of overcharged amounts along with interest under the applicable legal provisions.

Note (t) also addresses excess trade margins and provides for appropriate action, including possible prosecution.

The November 2026 notification does not create a new standalone penalty schedule. Any enforcement consequences must be assessed under the relevant governing provisions and the facts of the particular case.

What Happens After the NPPA Extension Ends on 15 January 2027?

The latest order provides for the continuation of the earlier knee implant price-control arrangement until 15 January 2027, unless amended by a subsequent notification.

The Gazette does not announce what NPPA will decide after that date. It also does not specify that a revised ceiling-price schedule will necessarily be issued.

Manufacturers, importers and healthcare institutions should monitor official NPPA communications as the date approaches.

Businesses should not assume that prices will become unrestricted immediately after the stated period. The applicable legal position will depend on the governing framework and any further orders issued by the authority.

How Can Corpseed Help With Medical Device Regulatory Compliance?

Businesses operating in India's medical device sector may have to deal with different regulatory requirements depending on whether they manufacture, import, distribute or market medical devices.

Alongside pricing-related obligations, separate requirements concerning medical device licensing, product classification and regulatory documentation may apply.

Corpseed provides medical device regulatory compliance services, including assistance with relevant CDSCO registration and import licensing processes.

Depending on the business requirement, Corpseed can assist with:

  • Medical device registration: Guidance on applicable registration and licensing requirements for medical devices in India.
  • Product classification support: Assistance in identifying relevant medical device categories and the corresponding regulatory route.
  • Medical device import licensing: Documentation and application assistance for applicable CDSCO import licences.
  • Regulatory documentation: Support in preparing and reviewing documentation for relevant medical device approvals.
  • Compliance coordination: Assistance with related regulatory processes falling within Corpseed's service areas.

The NPPA price extension does not make consultancy services compulsory, and CDSCO licensing assistance is separate from NPPA's authority to regulate prices.

Need professional support with medical device registration or import compliance in India? Contact Corpseed to discuss the regulatory requirements applicable to your business.

Key Takeaways

  • NPPA issued S.O. 6222(E) on 13 November 2026, extending the existing knee implant price-control arrangement until 15 January 2027, unless amended earlier.
  • The notification continues the earlier arrangement and does not itself announce revised numerical ceiling prices.
  • Notes (b) to (t) of the original S.O. 2668(E), dated 16 August 2017, remain applicable during the latest order's operation.
  • The relevant pricing framework covers specified components of primary and revision knee replacement systems.
  • Manufacturers, importers, distributors and healthcare institutions should review the applicable price-control and related compliance provisions.
  • Further changes, if any, must be established through subsequent official NPPA notifications.

Document Preview

Embedded reference document

Fullscreen β†—

Related

Explore more updates from the same department.

Call